Financhill
Buy
62

LNSR Quote, Financials, Valuation and Earnings

Last price:
$12.41
Seasonality move :
18.79%
Day range:
$12.40 - $12.71
52-week range:
$8.96 - $17.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.53x
P/B ratio:
33.92x
Volume:
32.3K
Avg. volume:
37.9K
1-year change:
34.18%
Market cap:
$151M
Revenue:
$53.5M
EPS (TTM):
-$4.39

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
LNSR
LENSAR, Inc.
$20.5M -$0.09 30.98% -90.51% $15.00
ADGM
Adagio Medical Holdings, Inc.
-- -$0.31 -100% -91.79% $4.00
INBS
Intelligent Bio Solutions, Inc.
$1.4M -- 160.36% -- --
LAB
Standard BioTools, Inc.
$18.5M -$0.03 -54.41% -72.53% $1.55
MOVE
Movano, Inc.
$3.4M -$7.10 76.06% -41.21% $30.00
NPCE
NeuroPace, Inc.
$24.7M -$0.17 -4.4% -6.27% $19.25
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
LNSR
LENSAR, Inc.
$12.64 $15.00 $151M -- $0.00 0% 2.53x
ADGM
Adagio Medical Holdings, Inc.
$1.03 $4.00 $21.8M 218.00x $0.00 0% 115.29x
INBS
Intelligent Bio Solutions, Inc.
$9.09 -- $8.7M -- $0.00 0% 8.21x
LAB
Standard BioTools, Inc.
$1.53 $1.55 $588.4M -- $0.00 0% 4.50x
MOVE
Movano, Inc.
$19.54 $30.00 $16.3M -- $0.00 0% 29.57x
NPCE
NeuroPace, Inc.
$16.23 $19.25 $540.6M -- $0.00 0% 5.45x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
LNSR
LENSAR, Inc.
-31.16% -0.941 1.79% 0.65x
ADGM
Adagio Medical Holdings, Inc.
106.35% 0.022 73.62% 0.48x
INBS
Intelligent Bio Solutions, Inc.
35.02% 2.237 21.48% 0.47x
LAB
Standard BioTools, Inc.
6.41% 0.680 5.49% 1.93x
MOVE
Movano, Inc.
212.35% 3.110 67.05% 0.29x
NPCE
NeuroPace, Inc.
79.36% 0.372 20.74% 3.82x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
LNSR
LENSAR, Inc.
$5.8M -$7.6M -684.94% -1013.45% -52.95% -$3.5M
ADGM
Adagio Medical Holdings, Inc.
-$531K -$5.7M -193.23% -340.49% -- -$3.5M
INBS
Intelligent Bio Solutions, Inc.
$214.9K -$2.9M -213.68% -255.54% -263.64% -$2.9M
LAB
Standard BioTools, Inc.
$9.5M -$23.5M -22.34% -24.44% -120.02% -$23.1M
MOVE
Movano, Inc.
-$200K -$2.6M -337.24% -410.28% -3238.75% -$1.6M
NPCE
NeuroPace, Inc.
$21.2M -$2.6M -27.09% -149.8% -9.51% -$2M

LENSAR, Inc. vs. Competitors

  • Which has Higher Returns LNSR or ADGM?

    Adagio Medical Holdings, Inc. has a net margin of -25.94% compared to LENSAR, Inc.'s net margin of --. LENSAR, Inc.'s return on equity of -1013.45% beat Adagio Medical Holdings, Inc.'s return on equity of -340.49%.

    Company Gross Margin Earnings Per Share Invested Capital
    LNSR
    LENSAR, Inc.
    40.56% -$0.31 -$9.2M
    ADGM
    Adagio Medical Holdings, Inc.
    -- -$0.66 $20.7M
  • What do Analysts Say About LNSR or ADGM?

    LENSAR, Inc. has a consensus price target of $15.00, signalling upside risk potential of 18.67%. On the other hand Adagio Medical Holdings, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 288.35%. Given that Adagio Medical Holdings, Inc. has higher upside potential than LENSAR, Inc., analysts believe Adagio Medical Holdings, Inc. is more attractive than LENSAR, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    LNSR
    LENSAR, Inc.
    0 2 0
    ADGM
    Adagio Medical Holdings, Inc.
    1 0 0
  • Is LNSR or ADGM More Risky?

    LENSAR, Inc. has a beta of 0.695, which suggesting that the stock is 30.495% less volatile than S&P 500. In comparison Adagio Medical Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock LNSR or ADGM?

    LENSAR, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adagio Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR, Inc. pays -- of its earnings as a dividend. Adagio Medical Holdings, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LNSR or ADGM?

    LENSAR, Inc. quarterly revenues are $14.3M, which are larger than Adagio Medical Holdings, Inc. quarterly revenues of --. LENSAR, Inc.'s net income of -$3.7M is higher than Adagio Medical Holdings, Inc.'s net income of -$10.1M. Notably, LENSAR, Inc.'s price-to-earnings ratio is -- while Adagio Medical Holdings, Inc.'s PE ratio is 218.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR, Inc. is 2.53x versus 115.29x for Adagio Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LNSR
    LENSAR, Inc.
    2.53x -- $14.3M -$3.7M
    ADGM
    Adagio Medical Holdings, Inc.
    115.29x 218.00x -- -$10.1M
  • Which has Higher Returns LNSR or INBS?

    Intelligent Bio Solutions, Inc. has a net margin of -25.94% compared to LENSAR, Inc.'s net margin of -269.38%. LENSAR, Inc.'s return on equity of -1013.45% beat Intelligent Bio Solutions, Inc.'s return on equity of -255.54%.

    Company Gross Margin Earnings Per Share Invested Capital
    LNSR
    LENSAR, Inc.
    40.56% -$0.31 -$9.2M
    INBS
    Intelligent Bio Solutions, Inc.
    19.33% -$0.35 $5.4M
  • What do Analysts Say About LNSR or INBS?

    LENSAR, Inc. has a consensus price target of $15.00, signalling upside risk potential of 18.67%. On the other hand Intelligent Bio Solutions, Inc. has an analysts' consensus of -- which suggests that it could grow by 1220.13%. Given that Intelligent Bio Solutions, Inc. has higher upside potential than LENSAR, Inc., analysts believe Intelligent Bio Solutions, Inc. is more attractive than LENSAR, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    LNSR
    LENSAR, Inc.
    0 2 0
    INBS
    Intelligent Bio Solutions, Inc.
    0 0 0
  • Is LNSR or INBS More Risky?

    LENSAR, Inc. has a beta of 0.695, which suggesting that the stock is 30.495% less volatile than S&P 500. In comparison Intelligent Bio Solutions, Inc. has a beta of 4.455, suggesting its more volatile than the S&P 500 by 345.491%.

  • Which is a Better Dividend Stock LNSR or INBS?

    LENSAR, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR, Inc. pays -- of its earnings as a dividend. Intelligent Bio Solutions, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LNSR or INBS?

    LENSAR, Inc. quarterly revenues are $14.3M, which are larger than Intelligent Bio Solutions, Inc. quarterly revenues of $1.1M. LENSAR, Inc.'s net income of -$3.7M is lower than Intelligent Bio Solutions, Inc.'s net income of -$3M. Notably, LENSAR, Inc.'s price-to-earnings ratio is -- while Intelligent Bio Solutions, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR, Inc. is 2.53x versus 8.21x for Intelligent Bio Solutions, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LNSR
    LENSAR, Inc.
    2.53x -- $14.3M -$3.7M
    INBS
    Intelligent Bio Solutions, Inc.
    8.21x -- $1.1M -$3M
  • Which has Higher Returns LNSR or LAB?

    Standard BioTools, Inc. has a net margin of -25.94% compared to LENSAR, Inc.'s net margin of -162.05%. LENSAR, Inc.'s return on equity of -1013.45% beat Standard BioTools, Inc.'s return on equity of -24.44%.

    Company Gross Margin Earnings Per Share Invested Capital
    LNSR
    LENSAR, Inc.
    40.56% -$0.31 -$9.2M
    LAB
    Standard BioTools, Inc.
    48.51% -$0.09 $427M
  • What do Analysts Say About LNSR or LAB?

    LENSAR, Inc. has a consensus price target of $15.00, signalling upside risk potential of 18.67%. On the other hand Standard BioTools, Inc. has an analysts' consensus of $1.55 which suggests that it could grow by 1.31%. Given that LENSAR, Inc. has higher upside potential than Standard BioTools, Inc., analysts believe LENSAR, Inc. is more attractive than Standard BioTools, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    LNSR
    LENSAR, Inc.
    0 2 0
    LAB
    Standard BioTools, Inc.
    1 2 0
  • Is LNSR or LAB More Risky?

    LENSAR, Inc. has a beta of 0.695, which suggesting that the stock is 30.495% less volatile than S&P 500. In comparison Standard BioTools, Inc. has a beta of 1.264, suggesting its more volatile than the S&P 500 by 26.42%.

  • Which is a Better Dividend Stock LNSR or LAB?

    LENSAR, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR, Inc. pays -- of its earnings as a dividend. Standard BioTools, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LNSR or LAB?

    LENSAR, Inc. quarterly revenues are $14.3M, which are smaller than Standard BioTools, Inc. quarterly revenues of $19.6M. LENSAR, Inc.'s net income of -$3.7M is higher than Standard BioTools, Inc.'s net income of -$31.7M. Notably, LENSAR, Inc.'s price-to-earnings ratio is -- while Standard BioTools, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR, Inc. is 2.53x versus 4.50x for Standard BioTools, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LNSR
    LENSAR, Inc.
    2.53x -- $14.3M -$3.7M
    LAB
    Standard BioTools, Inc.
    4.50x -- $19.6M -$31.7M
  • Which has Higher Returns LNSR or MOVE?

    Movano, Inc. has a net margin of -25.94% compared to LENSAR, Inc.'s net margin of -5036.25%. LENSAR, Inc.'s return on equity of -1013.45% beat Movano, Inc.'s return on equity of -410.28%.

    Company Gross Margin Earnings Per Share Invested Capital
    LNSR
    LENSAR, Inc.
    40.56% -$0.31 -$9.2M
    MOVE
    Movano, Inc.
    -250% -$4.73 $1.5M
  • What do Analysts Say About LNSR or MOVE?

    LENSAR, Inc. has a consensus price target of $15.00, signalling upside risk potential of 18.67%. On the other hand Movano, Inc. has an analysts' consensus of $30.00 which suggests that it could grow by 1435.31%. Given that Movano, Inc. has higher upside potential than LENSAR, Inc., analysts believe Movano, Inc. is more attractive than LENSAR, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    LNSR
    LENSAR, Inc.
    0 2 0
    MOVE
    Movano, Inc.
    0 0 0
  • Is LNSR or MOVE More Risky?

    LENSAR, Inc. has a beta of 0.695, which suggesting that the stock is 30.495% less volatile than S&P 500. In comparison Movano, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock LNSR or MOVE?

    LENSAR, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Movano, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR, Inc. pays -- of its earnings as a dividend. Movano, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LNSR or MOVE?

    LENSAR, Inc. quarterly revenues are $14.3M, which are larger than Movano, Inc. quarterly revenues of $80K. LENSAR, Inc.'s net income of -$3.7M is higher than Movano, Inc.'s net income of -$4M. Notably, LENSAR, Inc.'s price-to-earnings ratio is -- while Movano, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR, Inc. is 2.53x versus 29.57x for Movano, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LNSR
    LENSAR, Inc.
    2.53x -- $14.3M -$3.7M
    MOVE
    Movano, Inc.
    29.57x -- $80K -$4M
  • Which has Higher Returns LNSR or NPCE?

    NeuroPace, Inc. has a net margin of -25.94% compared to LENSAR, Inc.'s net margin of -12.78%. LENSAR, Inc.'s return on equity of -1013.45% beat NeuroPace, Inc.'s return on equity of -149.8%.

    Company Gross Margin Earnings Per Share Invested Capital
    LNSR
    LENSAR, Inc.
    40.56% -$0.31 -$9.2M
    NPCE
    NeuroPace, Inc.
    77.39% -$0.11 $89.7M
  • What do Analysts Say About LNSR or NPCE?

    LENSAR, Inc. has a consensus price target of $15.00, signalling upside risk potential of 18.67%. On the other hand NeuroPace, Inc. has an analysts' consensus of $19.25 which suggests that it could grow by 18.61%. Given that LENSAR, Inc. has higher upside potential than NeuroPace, Inc., analysts believe LENSAR, Inc. is more attractive than NeuroPace, Inc..

    Company Buy Ratings Hold Ratings Sell Ratings
    LNSR
    LENSAR, Inc.
    0 2 0
    NPCE
    NeuroPace, Inc.
    7 0 0
  • Is LNSR or NPCE More Risky?

    LENSAR, Inc. has a beta of 0.695, which suggesting that the stock is 30.495% less volatile than S&P 500. In comparison NeuroPace, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock LNSR or NPCE?

    LENSAR, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroPace, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. LENSAR, Inc. pays -- of its earnings as a dividend. NeuroPace, Inc. pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios LNSR or NPCE?

    LENSAR, Inc. quarterly revenues are $14.3M, which are smaller than NeuroPace, Inc. quarterly revenues of $27.4M. LENSAR, Inc.'s net income of -$3.7M is lower than NeuroPace, Inc.'s net income of -$3.5M. Notably, LENSAR, Inc.'s price-to-earnings ratio is -- while NeuroPace, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for LENSAR, Inc. is 2.53x versus 5.45x for NeuroPace, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    LNSR
    LENSAR, Inc.
    2.53x -- $14.3M -$3.7M
    NPCE
    NeuroPace, Inc.
    5.45x -- $27.4M -$3.5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will ISRG Stock Be in 5 Years?
Where Will ISRG Stock Be in 5 Years?

Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…

Is Kratos Stock a Good Investment?
Is Kratos Stock a Good Investment?

UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…

Is Palantir Stock Going to Crash?
Is Palantir Stock Going to Crash?

AI and data analytics major Palantir (NASDAQ:PLTR) has become something…

Stock Ideas

Buy
59
Is NVDA Stock a Buy?

Market Cap: $4.5T
P/E Ratio: 63x

Buy
61
Is GOOG Stock a Buy?

Market Cap: $4T
P/E Ratio: 41x

Sell
50
Is GOOGL Stock a Buy?

Market Cap: $4T
P/E Ratio: 41x

Alerts

Buy
52
CVLT alert for Jan 27

Commvault Systems, Inc. [CVLT] is down 31.22% over the past day.

Buy
73
BNAI alert for Jan 27

Brand Engagement Network, Inc. [BNAI] is down 16.85% over the past day.

Buy
71
SANM alert for Jan 27

Sanmina Corp. [SANM] is down 21.58% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock